Hi all just out I found this Edison report on https://www.research-tree.com/sector/health
its dated 25th January. It shows a 46& growth in the USA business,
best regards to all from fpThe company recently reported results for H1 FY21, featuring a 46% y-o-y increase in Cxbladder sales to NZ$3.3m. The US business grew 46% to NZ$2.9m and was assisted by the inclusion of Cxbladder into a local coverage determination (LCD) enabling reimbursement at US$760 per test from the US Centers for Medicare and Medicaid Services (CMS) on all tests after 1 July (corresponding to the second half of H1 FY21). The outlook for growth in the US business is strong due to the change in reimbursement, the Kaiser Permanente commercial agreement and the company’s intensified investment in its US operations.
- Forums
- ASX - By Stock
- PEB
- Increasing sales
PEB
pacific edge limited
Add to My Watchlist
3.13%
!
9.9¢

Increasing sales
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online